DiNAQOR ^Company

DiNAQOR is a gene therapy platform company that focuses on developing innovative solutions for patients with heart disease, specifically genetic cardiomyopathies. Their lead preclinical program, DiNA-001, is focused on treating MYBPC3-linked cardiomyopathy. The company was founded in 2019 and is based in Pf\xe4ffikon, Switzerland. They are also a life sciences platform company that specializes in human-based tissue drug development and technology for organ-specific delivery of gene therapies and other therapeutics.